Search Results for: AC Immune SA to Receive
Articles
July 19, 2011
7/26/2011 July 19, 2011
Daiichi Sankyo Launches Direct Oral Factor Xa Inhibitor Daiichi Sankyo Company, Limited recently announced the launch of LIXIANA (JAN: Edoxaban...
July 11, 2011
Evotec & Roche to Jointly Develop Biomarkers in Oncology July 11, 2011
Evotec AG and Roche recently announced a collaboration in novel protein activity based biomarkers for Roche's oncology drugs under development....
July 6, 2011
7/12/2011 July 6, 2011
Evotec & Roche to Jointly Develop Biomarkers in Oncology Evotec AG and Roche recently announced a collaboration in novel...
May 5, 2011
5/10/2011 May 5, 2011
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study QRxPharma Limited recently announced it has completed patient enrolment for...
April 7, 2011
4/12/2011 April 7, 2011
IBM & the Institute of Bioengineering & Nanotechnology Find Breakthrough TreatmentResearchers from IBM and the Institute of Bioengineering and Nanotechnology...
March 27, 2011
3/29/2011 March 27, 2011
Champions Biotechnology Announces Technology Collaboration With CephalonChampions Biotechnology, Inc. recently announced the signing of a technology collaboration agreement with Cephalon,...
March 27, 2011
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Abbott Laboratories March 27, 2011
Seattle Genetics, Inc. recently announced it has entered into a collaboration agreement with Abbott under which Abbott will pay an...
March 13, 2011
3/15/2011 March 13, 2011
Cytheris Announces Study Results Indicating CYT107 Expands CD4 T-Cells Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development...
March 13, 2011
Cytheris Announces Study Results Indicating CYT107 Expands CD4 T-Cells March 13, 2011
Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, recently announced results...
January 17, 2011
Amgen & Xencor to Co-Develop Novel Antibody; Deal Worth $500 Million January 17, 2011
Xencor, Inc. and Amgen recently announced they will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and...
January 12, 2011
1/18/2011 January 12, 2011
Amgen & Xencor to Co-Develop Novel Antibody; Deal Worth $500 Million Xencor, Inc. and Amgen recently announced they will collaborate to...
